Regular Hours
|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
| Valuation Estimation |
|
EPS (Current/Estimated)
15.28/17.38
|
|
Enterprise Value
12.14B
|
| Balance Sheet |
|
Book Value Per Share
16.18
|
| Cash Flow |
|
Cash Flow Yield
0.06
|
| Income Statement |
|
Total Revenue
2.53B
|
|
Operating Revenue Per Share
62.79
|
|
Industry Comparison
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
|
Business Description
|
|||
| Medpace is a late-stage contract research organization that provides full-service drug-development and clinical trial services to small and midsize biotechnology, pharmaceutical, and medical device firms. It also offers ancillary services,including bioanalytical laboratory services and imaging capabilities. The company was founded over 30 years ago and has more than 5,400 employees across 40 countries. Medpace is headquartered in Cincinnati, Ohio, and its operations are primarily based in the US, with additional presence in Europe, Asia, South America, Africa, and Australia. Cinven, a global private equity firm, acquired Medpace for $915 million in 2014 and exited its investment in 2018. |

413.63 
